DDInter1001 DDInter1658
Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation.
Selpercatinib is a kinase inhibitor with enhanced specificity for RET tyrosine kinase receptors (RTKs) over other RTK classes.[A202055, A202052, L13604] Enhanced RET (Rearranged during transfection) oncogene expression is a hallmark of many cancers. Although multikinase inhibitors, including [cabozantinib], [ponatinib], [sorafenib], [sunitinib], and [vandetanib], have shown efficacy in RET-driven cancers, their lack of specificity is generally associated with substantial toxicity. Selpercatinib (LOXO-292) and pralsetinib (BLU-667) represent the first generation of specific RET RTK inhibitors for the treatment of RET-driven cancers.[A202049, A202055, A202052, L13604] Although selpercatinib is currently still under investigation in clinical trial NCT04211337, it was granted accelerated FDA approval on May 8, 2020, for specific RET-driven cancer indications. It is currently marketed under the brand name RETEVMO™ by Loxo Oncology Inc. Selpercatinib is also approved by the European Commission.
Ixabepilone {u} (Compound) treats {v} (Disease) breast cancer
Ixabepilone {u} (Compound) binds {v} (Gene) TUBB3
Ixabepilone {u} (Compound) is included by {v} (Pharmacologic Class) Microtubule Inhibition
Ixabepilone {u} (Compound) causes {v} (Side Effect) Dehydration
Ixabepilone {u} may cause a minor interaction that can limit clinical effects when taken with {v} Capecitabine
Ixabepilone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Imatinib
Ixabepilone {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Troleandomycin
Ixabepilone {u} may lead to a major life threatening interaction when taken with {v} Clozapine
Ixabepilone {u} may lead to a major life threatening interaction when taken with {v} Measles virus vaccine live attenuated
Ixabepilone (Compound) treats breast cancer (Disease)
Ixabepilone (Compound) binds TUBB3 (Gene)
Ixabepilone (Compound) is included by Microtubule Inhibition (Pharmacologic Class)
Ixabepilone (Compound) causes Dehydration (Side Effect)
Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Capecitabine
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Imatinib
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin
Ixabepilone may lead to a major life threatening interaction when taken with Clozapine
Ixabepilone may lead to a major life threatening interaction when taken with Measles virus vaccine live attenuated